NASDAQ:CWBR - CohBar Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.50
  • Forecasted Upside: 354.55 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$1.21
▼ -0.01 (-0.82%)
1 month | 3 months | 12 months
Get New CohBar Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CWBR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CWBR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$5.50
▲ +354.55% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for CohBar in the last 3 months. The average price target is $5.50, with a high forecast of $8.00 and a low forecast of $3.50. The average price target represents a 354.55% upside from the last price of $1.21.
Buy
The current consensus among 5 contributing investment analysts is to buy stock in CohBar.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/18/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/16/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/14/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/31/2021AegisReiterated RatingBuyHigh
i
Rating by N. Weinstein at Aegis
3/31/2021Chardan CapitalBoost Price TargetBuy$3.00 ➝ $3.50High
i
Rating by M. Morabito at Chardan Capital
3/22/2021AegisInitiated CoverageBuy$6.00High
i
3/15/2021AegisInitiated CoverageBuy$6.00High
i
12/23/2020Chardan CapitalReiterated RatingBuyN/A
i
Rating by M. Morabito at Chardan Capital
12/17/2020Chardan CapitalInitiated CoverageBuy$3.00High
i
11/10/2020Roth CapitalReiterated RatingMarket Perform ➝ Buy$8.00High
i
10/15/2020WBB SecuritiesInitiated CoverageBuy$4.50High
i
9/17/2020Roth CapitalReiterated RatingBuy$8.00Low
i
Rating by E. Piros at Roth Capital
9/17/2020Roth CapitalInitiated CoverageBuy$8.00Low
i
5/28/2020Brookline Capital ManagementInitiated CoverageBuyN/A
i
5/27/2020Brookline Capital ManagementReiterated RatingBuyMedium
i
Rating by K. Raja at Brookline Capital Management
(Data available from 4/14/2016 forward)
CohBar logo
CohBar, Inc., a clinical stage biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial-derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases, CB5064 analogs for COVID-19 associated ARDS, MBT5 analogs for CXCR4-related cancer and orphan diseases, and MBT3 analogs for cancer immunotherapy. The company was founded in 2007 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $1.21
$1.19
$1.22

50 Day Range

MA: $1.45
$1.26
$1.68

52 Week Range

Now: $1.21
$0.85
$4.25

Volume

1,796 shs

Average Volume

693,704 shs

Market Capitalization

$74.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.96

Frequently Asked Questions

What sell-side analysts currently cover shares of CohBar?

The following Wall Street analysts have issued research reports on CohBar in the last twelve months: Aegis, Brookline Capital Management, Chardan Capital, Roth Capital, WBB Securities, and Zacks Investment Research.
View the latest analyst ratings for CWBR.

What is the current price target for CohBar?

4 Wall Street analysts have set twelve-month price targets for CohBar in the last year. Their average twelve-month price target is $5.50, suggesting a possible upside of 343.5%. Roth Capital has the highest price target set, predicting CWBR will reach $8.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $3.50 for CohBar in the next year.
View the latest price targets for CWBR.

What is the current consensus analyst rating for CohBar?

CohBar currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CWBR will outperform the market and that investors should add to their positions of CohBar.
View the latest ratings for CWBR.

What other companies compete with CohBar?

How do I contact CohBar's investor relations team?

CohBar's physical mailing address is 1455 Adams Drive Suite 2050, Menlo Park CA, 94025. The company's listed phone number is 650 446 7888 and its investor relations email address is [email protected] The official website for CohBar is www.cohbar.com.